156 related articles for article (PubMed ID: 27443611)
21. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
Belshe RB; Frey SE; Graham I; Mulligan MJ; Edupuganti S; Jackson LA; Wald A; Poland G; Jacobson R; Keyserling HL; Spearman P; Hill H; Wolff M;
J Infect Dis; 2011 Mar; 203(5):666-73. PubMed ID: 21282194
[TBL] [Abstract][Full Text] [Related]
23. Improved immune responses against avian influenza virus following oral vaccination of chickens with HA DNA vaccine using attenuated Salmonella typhimurium as carrier.
Jazayeri SD; Ideris A; Zakaria Z; Yeap SK; Omar AR
Comp Immunol Microbiol Infect Dis; 2012 Sep; 35(5):417-27. PubMed ID: 22512819
[TBL] [Abstract][Full Text] [Related]
24. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
Crevar CJ; Carter DM; Lee KY; Ross TM
Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
[TBL] [Abstract][Full Text] [Related]
25. Protection of White Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus.
Bertran K; Balzli C; Lee DH; Suarez DL; Kapczynski DR; Swayne DE
Vaccine; 2017 Nov; 35(46):6336-6344. PubMed ID: 28554502
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
27. Experimental challenge of chicken vaccinated with commercially available H5 vaccines reveals loss of protection to some highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China.
Connie Leung YH; Luk G; Sia SF; Wu YO; Ho CK; Chow KC; Tang SC; Guan Y; Malik Peiris JS
Vaccine; 2013 Aug; 31(35):3536-42. PubMed ID: 23791547
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses.
Kapczynski DR; Tumpey TM; Hidajat R; Zsak A; Chrzastek K; Tretyakova I; Pushko P
Vaccine; 2016 Mar; 34(13):1575-1581. PubMed ID: 26868083
[TBL] [Abstract][Full Text] [Related]
29. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
30. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ
Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100
[TBL] [Abstract][Full Text] [Related]
31. Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.
Jegaskanda S; Mason RD; Andrews SF; Wheatley AK; Zhang R; Reynoso GV; Ambrozak DR; Santos CP; Luke CJ; Matsuoka Y; Brenchley JM; Hickman HD; Talaat KR; Permar SR; Liao HX; Yewdell JW; Koup RA; Roederer M; McDermott AB; Subbarao K
J Virol; 2018 May; 92(9):. PubMed ID: 29444938
[TBL] [Abstract][Full Text] [Related]
32. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxicity and immunological responses following oral vaccination of nanoencapsulated avian influenza virus H5 DNA vaccine with green synthesis silver nanoparticles.
Jazayeri SD; Ideris A; Zakaria Z; Shameli K; Moeini H; Omar AR
J Control Release; 2012 Jul; 161(1):116-23. PubMed ID: 22549012
[TBL] [Abstract][Full Text] [Related]
36. Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.
Ross KA; Loyd H; Wu W; Huntimer L; Ahmed S; Sambol A; Broderick S; Flickinger Z; Rajan K; Bronich T; Mallapragada S; Wannemuehler MJ; Carpenter S; Narasimhan B
Int J Nanomedicine; 2015; 10():229-43. PubMed ID: 25565816
[TBL] [Abstract][Full Text] [Related]
37. Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses.
Kapczynski DR; Pantin-Jackwood MJ; Spackman E; Chrzastek K; Suarez DL; Swayne DE
Vaccine; 2017 Nov; 35(46):6345-6353. PubMed ID: 28456525
[TBL] [Abstract][Full Text] [Related]
38. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
[TBL] [Abstract][Full Text] [Related]
39. Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.
Winokur PL; Patel SM; Brady R; Chen WH; El-Kamary SS; Edwards K; Creech CB; Frey S; Keitel WA; Belshe R; Walter E; Bellamy A; Hill H
J Infect Dis; 2015 Aug; 212(4):525-30. PubMed ID: 25712967
[TBL] [Abstract][Full Text] [Related]
40. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model.
Sabarth N; Howard MK; Savidis-Dacho H; van Maurik A; Barrett PN; Kistner O
Vaccine; 2010 Jan; 28(3):650-6. PubMed ID: 19896446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
